Continue Reading
Full article on Yahoo Finance
Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion
Market Intelligence Analysis
AI-Powered
Why This Matters
Eli Lilly's acquisition of Orna Therapeutics for $2.4 billion is expected to boost its presence in the biotechnology sector, particularly in RNA drug development.
Market Impact
Market impact analysis based on bullish sentiment with 90% confidence.
Sentiment
Bullish
AI Confidence
90%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Eli Lilly shares rose Monday after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash. The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said on Monday. Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.
Original article published by
Yahoo Finance
on February 9, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.